Feeding Farmed Animals While People Starve: Humane Foundation Calls for Urgent Rethink of Global Food Priorities

LONDON, UK – As the world faces escalating hunger, climate instability, and social inequality, the Humane Foundation is calling for an urgent global shift in how food is produced and distributed — starting with a critical look at the role of industrial animal farming in perpetuating scarcity and injustice.

Every year, billions of animals raised for meat, dairy, and eggs consume enormous quantities of crops — crops that could instead nourish hungry people. This deeply flawed system, built on industrial-scale efficiency and profit, has led to a global paradox: a planet that produces more than enough food to feed everyone, yet leaves over 800 million people malnourished or food insecure.

“We’re not facing a food shortage. We’re facing a food justice crisis,” said A. Roghani, Executive Director of the Humane Foundation. “We grow vast amounts of soy, corn, and grain — not to feed people, but to fatten animals in factory farms. It’s an irrational system, and it’s harming both humans and animals on a massive scale.”

The Injustice of Industrial Animal Farming

At the heart of the Humane Foundation’s call to action is a simple but unsettling reality: more than one-third of the world’s crops are used not to feed people, but to feed livestock.

  • Over 70% of global soy and nearly one-third of grain production is funneled into factory farms.

  • It takes up to 16 pounds of grain to produce just one pound of beef.

  • Vast tracts of land — including ecologically sensitive areas — are cleared to grow feed for animals instead of nourishing human communities.

This inefficiency leads not only to food waste, but to worsening global hunger. Crops grown in the Global South are often exported to feed animals in the Global North, while local communities are left without access to affordable, nutritious food. Entire regions lose access to fertile land, clean water, and food sovereignty — all sacrificed in service of a meat-heavy system dominated by multinational corporations.

“When children go hungry while soybeans grown next door are shipped off to feed pigs in Europe or China, we have to ask ourselves: Who is this system really feeding?” said Roghani.

Starving the Planet to Feed the Few

Industrial animal agriculture doesn’t just displace food — it devours resources. In addition to crops, factory farming consumes:

  • One-third of the world’s freshwater, largely for feed irrigation.

  • More land than any other human activity, contributing to deforestation and desertification.

  • More greenhouse gas emissions than all the world’s cars, planes, and ships combined.

The result is a system that exacerbates climate breakdown — one of the greatest threats to food security in the coming decades. As weather patterns become more extreme and crop yields become more volatile, the most vulnerable populations — especially in the Global South — will bear the brunt of food shortages, price spikes, and famine.

“Factory farming is fueling the climate crisis that will make future hunger inevitable,” said Roghani. “It’s the definition of unsustainable — and inhumane.”

Animal Cruelty and Human Suffering: Two Sides of the Same Coin

While industrial animal farming is often criticized for its cruelty toward animals — confining billions of sentient beings in cramped, filthy, and unnatural conditions — the Humane Foundation stresses that the human consequences of this system are equally dire.

  • Farm workers in many countries endure unsafe, exploitative conditions for low pay.

  • Rural communities lose their land, water, and independence to powerful agribusinesses.

  • Entire nations are locked into export economies that feed animals abroad while their own people struggle to access basic nutrition.

The ethical cost is steep. The Foundation argues that continuing to prioritize cheap meat over food justice represents not just a policy failure, but a moral one.

A Call for a Compassionate Food System

The Humane Foundation is urging governments, civil society organizations, and individuals to rethink the food system from the ground up. That means:

  • Shifting subsidies away from industrial meat and toward plant-based agriculture.

  • Supporting farmers who grow food for people, not feed for animals.

  • Investing in local food systems that prioritize food security, not exports.

  • Encouraging more plant-based eating at every level — from homes to schools to public institutions.

“We can build a food system that nourishes everyone — not just those who can afford meat every day,” said Roghani. “It’s not just possible. It’s necessary.”

A More Humane Future Is Within Reach

The Humane Foundation envisions a world where food is produced ethically, shared equitably, and consumed responsibly. A world where animals are not confined in misery, and where people are not forced to choose between feeding themselves or feeding a system that profits from exploitation.

“Ending factory farming isn’t just an animal rights issue,” Roghani concluded. “It’s a human rights issue. It’s an environmental issue. It’s a survival issue. And the time to act is now.”

About the Humane Foundation

The Humane Foundation is a UK-based nonprofit working to dismantle the cruelty and injustice of industrial animal agriculture. Through its investigative platform Cruelty.farm, the Foundation exposes the hidden impacts of factory farming on animals, people, and the planet — and advocates for a more compassionate and sustainable future for all beings.

Media Contact
Company Name: Humane Foundation
Contact Person: Ali Roghani
Email: Send Email
Address:27 Old Gloucester Street
City: London
State: England
Country: United Kingdom
Website: https://cruelty.farm/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Feeding Farmed Animals While People Starve: Humane Foundation Calls for Urgent Rethink of Global Food Priorities

Nation One Mortgage Selects Aidium to Power Ambitious Growth Strategy and Technology Consolidation

Boulder, CO – Aidium is pleased to announce that they have partnered with Nation One Mortgage as their enterprise Mortgage CRM solution. Together, they will consolidate Nation One’s technology stack and establish a scalable foundation for their ambitious expansion plans.

Nation One Mortgage, a fast-growing lender known for its strong builder partnerships with industry leaders like Horton and Ryan Homes, has chosen Aidium to replace its existing CRM and dashboard systems with a single, unified platform designed to streamline operations before scaling across multiple new regions.

The strategic partnership will enable Nation One to achieve three critical business objectives: operational scalability, enhanced partner relationships, and accelerated revenue growth. By unifying disparate systems into a single platform, Nation One will create the technological foundation needed to support its ambitious expansion plans while strengthening connections with their partners.

“We needed a platform that could grow with us,” said Phil Crescenzo, Southeast Vice President at Nation One Mortgage. “What impressed us about Aidium was not just its ability to handle our current operations, but its scalability to support our planned expansion. The platform’s flexibility allows us to maintain our business model while providing the structure we need to scale efficiently.”

“Working with forward-thinking mortgage companies like Nation One that are strategically preparing for growth is exactly what Aidium was built for,” said Tony Farnsworth, VP of Sales at Aidium. “By establishing a strong operational foundation with our platform before expanding into new regions, Nation One is taking the smart approach to scaling their business. We’re excited to support their growth every step of the way.”

The implementation will bridge Nation One’s enterprise needs and their loan officers’ daily operations. This approach ensures the platform meets the specific requirements of Nation One’s highly successful operational model, which will then be scaled across new regions as they expand.

The partnership represents Aidium’s commitment to serving mortgage enterprises with ambitious growth plans, providing the technology foundation that enables operational efficiency while scaling.

About Aidium:

Aidium bridges the gap between loan officers’ needs and the enterprise’s, uniting teams on a single CRM. At its core, Aidium is an enterprise-grade CRM with team-level customization, advanced AI, marketing, reporting, and data capabilities that help mortgage businesses eliminate data silos, increase adoption rates, and deliver measurable ROI.

Media Contact
Company Name: Aidium
Contact Person: Greg Kassardjian
Email: Send Email
Country: United States
Website: https://thinkaidium.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Nation One Mortgage Selects Aidium to Power Ambitious Growth Strategy and Technology Consolidation

First Option Mortgage Selects Aidium as Enterprise CRM Platform to Centralize Operations

Boulder, CO – Aidium is pleased to announce that First Option Mortgage has selected Aidium’s comprehensive Mortgage CRM Platform to replace their existing system and create a unified technology ecosystem for their team of loan officers.

First Option Mortgage, an Atlanta-based lender known for its innovative approach to mortgage technology, cited Aidium’s platform flexibility and innovative architecture as key factors in its decision. The partnership aligns with First Option’s strategic vision of creating a seamlessly connected technology ecosystem that adapts to its unique operational model.

“We’ve always believed that technology should adapt to our business processes, not the other way around,” said POC at First Option Mortgage. “What stood out about Aidium was our shared vision of innovation using AI to revolutionize the mortgage industry. The platform’s flexible API architecture will allow us to build out the integrations we need, creating the exact mortgage technology ecosystem we’ve envisioned with Aidium as the central platform connecting everything together.”

The implementation will showcase Aidium’s industry-leading integration capabilities and flexible architecture, which are key differentiators in the mortgage CRM space. First Option will leverage Aidium’s open API to create a truly connected ecosystem that reflects its forward-thinking mortgage technology approach.

“We’re excited to partner with First Option Mortgage,” said Tony Farnsworth, VP of Sales at Aidium. “Their strategic approach to technology integration and commitment to creating a unified experience for their teams aligns perfectly with our platform’s capabilities.”

The partnership highlights Aidium’s rapid product development and commitment to leading the mortgage CRM industry with innovative solutions. First Option’s technical sophistication and dedication to building a best-in-class mortgage technology stack perfectly align with Aidium’s vision for the future of mortgage technology.

About Aidium:

Aidium bridges the gap between loan officers’ needs and the enterprise’s, uniting teams on a single CRM. At its core, Aidium is an enterprise-grade CRM with team-level customization, advanced AI, marketing, reporting, and data capabilities that help mortgage businesses eliminate data silos, increase adoption rates, and deliver measurable ROI.

Media Contact
Company Name: Aidium
Contact Person: Greg Kassardjian
Email: Send Email
Country: United States
Website: https://thinkaidium.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: First Option Mortgage Selects Aidium as Enterprise CRM Platform to Centralize Operations

Rapid Mortgage Company Selects Aidium as Enterprise CRM Platform to Consolidate Technology Stack and Drive Revenue Growth

Boulder, CO – Aidium is thrilled to announce that Rapid Mortgage Company has selected Aidium as a partner to unify their marketing and customer relationship management operations with a single, integrated solution.

Rapid Mortgage Company, a referral-driven mortgage lender experiencing adoption challenges with its legacy systems, will implement Aidium to address operational inefficiencies. This strategic partnership aims to resolve key enterprise challenges while enhancing the loan officer experience, improving adoption rates, and strengthening referral partner relationships.

“We chose Aidium because it delivers on what matters most to our business—a system our loan officers will actually use that still gives our enterprise the visibility we need,” said Cheri Booth, Director of Marketing at Rapid Mortgage Company. “The platform’s ability to balance powerful enterprise capabilities with an intuitive user experience is what sets it apart from other options we considered.”

The decision to partner with Aidium was driven by several key factors that directly align with Rapid Mortgage’s organizational requirements:

  • Enterprise-wide oversight: Aidium fully controls company-wide messaging, compliance, and automation to support scalable, consistent communication across all channels.

  • Platform consolidation: The partnership enables Rapid Mortgage to streamline CRM and marketing tools into a single solution for operational efficiency.

  • Predictive modeling: Aidium delivers powerful data insights to help identify clients likely to re-enter the market, fueling timely outreach and repeat business opportunities.

  • Coaching alignment: The platform’s robust reporting and accountability tools support Rapid Mortgage’s internal coaching initiatives and promote adoption at the user level.

  • 24/7 live support: Rapid Mortgage will benefit from around-the-clock access to knowledgeable support staff—a rare offering in the CRM space.

“This partnership represents a significant step forward,” said Tony Farnsworth, VP of Sales at Aidium. “By consolidating multiple systems into one unified platform, Rapid Mortgage will not only save on technology costs but will gain unprecedented visibility into their business operations while empowering their loan officers with tools that enhance productivity rather than create additional work.”

Aidium’s unified platform approach will allow Rapid to strengthen referral partner relationships, gain comprehensive business intelligence, identify new revenue opportunities, and streamline workflows—all while significantly improving technology adoption across the organization.

About Aidium:

Aidium bridges the gap between loan officers’ needs and the enterprise’s, uniting teams on a single CRM. At its core, Aidium is an enterprise-grade CRM with team-level customization, advanced AI, marketing, reporting, and data capabilities that help mortgage businesses eliminate data silos, increase adoption rates, and deliver measurable ROI.

Media Contact
Company Name: Aidium
Contact Person: Greg Kassardjian
Email: Send Email
Country: United States
Website: https://thinkaidium.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Rapid Mortgage Company Selects Aidium as Enterprise CRM Platform to Consolidate Technology Stack and Drive Revenue Growth

Discreet Services, Inc. Expands Elite Private Investigation Services to Colorado Springs

“Colorado Springs Private Investigator Services”
Discreet Services, Inc., a nationally recognized private investigation firm, announces the launch of its professional investigative services in Colorado Springs, Colorado. Specializing in bug sweeps (TSCM), child custody cases, infidelity investigations, and more, the firm brings high-level experience and discretion to families and individuals seeking truth and security.

Colorado Springs, CO – May 26, 2025 – Discreet Services, Inc., a trusted name in professional private investigations, is proud to announce the expansion of its services to Colorado Springs, Colorado. With a focus on technical surveillance countermeasures (TSCM), child custody investigations, infidelity cases, and background checks, the firm aims to provide local clients with the same expert-level discretion and results that have earned it national recognition.

“As Colorado Springs continues to grow, so does the need for professional, ethical investigative services,” said Jason Beberniss, a spokesperson for Discreet Services, Inc., “Our team is fully licensed, experienced, and equipped with state-of-the-art tools to uncover the truth—whether it’s locating hidden surveillance devices, supporting a family law case, or verifying someone’s past.”

Discreet Services, Inc. specializes in bug sweeps and TSCM inspections, using advanced equipment to detect hidden cameras, listening devices, GPS trackers, and other unauthorized surveillance. These services are increasingly in demand among high-profile individuals, business owners, and anyone concerned about privacy and data security.

The firm also conducts child custody and family law investigations, gathering evidence that supports legal proceedings through surveillance, interviews, and background research. Additionally, Discreet Services handles infidelity investigations, helping clients obtain clear, court-admissible proof in delicate personal matters.

Core Services Now Available in Colorado Springs:

  • Technical Surveillance Countermeasures (TSCM) / Bug Sweeps

  • Hidden Camera and GPS Tracker Detection

  • Child Custody and Family Law Investigations

  • Background Checks and Due Diligence

  • Infidelity Surveillance and Investigations

Discreet Services, Inc. operates with a commitment to confidentiality, legal compliance, and client trust. Every investigation is tailored to meet the unique needs of the case, and clients are kept informed throughout the process.

For more information or to schedule a free consultation in Colorado Springs, call 720-871-4602 or visit www.discreetpi.com.

Media Contact
Company Name: Discreet Services, Inc.
Contact Person: Jason Beberniss
Email: Send Email
Phone: 720-871-4602
City: Colorado Springs
State: CO
Country: United States
Website: www.discreetpi.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Discreet Services, Inc. Expands Elite Private Investigation Services to Colorado Springs

Las Vegas Car Accident Lawyers, LLP Expands Personal Injury Legal Services Across Las Vegas

“The expansion includes additional consultation rooms and upgraded legal technology, reaffirming the firm’s position as a top Las Vegas car accident law firm.”
Las Vegas Car Accident Lawyers, LLP is proud to announce the expansion of its personal injury legal services throughout Las Vegas, NV. In addition to car accident representation, the firm now handles pedestrian injuries, rideshare accidents, slip and falls, and wrongful death claims. With free consultations and no fees unless you win, the firm is committed to helping injury victims recover the compensation they deserve. Learn more at https://lasvegascaraccidentlawyer.vegas

Las Vegas, NV – May 26, 2025 – Las Vegas Car Accident Lawyers, LLP, a trusted name in auto injury representation, is proud to announce the expansion of its personal injury legal services to serve clients across the greater Las Vegas area. With a renewed focus on accident victims and injury claims, the firm now offers comprehensive legal representation for a wider range of personal injury matters, including slip and falls, pedestrian accidents, rideshare incidents, and wrongful death cases.

As traffic volume, tourism, and population density continue to rise in Las Vegas, the demand for qualified and aggressive legal representation has never been greater. The firm’s expansion ensures that more Nevadans—both residents and visitors—have access to experienced legal counsel when accidents strike.

“We’ve built a reputation on results in car accident litigation, and now we’re bringing that same level of focus and advocacy to all areas of personal injury,” said a spokesperson for the firm. “Our mission is simple: protect the rights of injury victims and help them recover what they’re owed.”

Services Now Include:

  • Auto and motorcycle accident claims

  • Pedestrian and crosswalk injury cases

  • Rideshare (Uber & Lyft) liability claims

  • Slip and fall / premises liability

  • Catastrophic injury and wrongful death litigation

  • Insurance claim denials and bad faith cases

Victims of negligence can expect personalized attention, aggressive negotiation, and no legal fees unless the firm wins their case. Consultations remain 100% free and confidential.

To learn more or schedule a case review, visit https://lasvegascaraccidentlawyer.vegas.

About Las Vegas Car Accident Lawyers, LLP

Las Vegas Car Accident Lawyers, LLP is a Nevada-based personal injury law firm dedicated to representing individuals who have been injured due to the negligence of others. With a client-first approach and deep understanding of Nevada tort law, the firm has secured favorable outcomes for countless injury victims across Clark County.

Media Contact
Company Name: Las Vegas Car Accident Lawyer
Contact Person: James Dean
Email: Send Email
Address:300 S 4th St 6th Floor
City: Las Vegas
State: Nevada
Country: United States
Website: https://lasvegascaraccidentlawyer.vegas/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Las Vegas Car Accident Lawyers, LLP Expands Personal Injury Legal Services Across Las Vegas

Interstitial Lung Disease Market Poised for Significant Growth from 2023 to 2032, Reports DelveInsight | J2H Biotech, Crystec Pharma, Apie Therapeutics, BLR Bio, ImmunoMet Therapeutics, AdAlta

The Key Interstitial Lung Disease Companies in the market include – J2H Biotech, Crystec Pharma, Apie Therapeutics, BLR Bio, ImmunoMet Therapeutics, AdAlta Limited, Genentech, Bristol-Myers Squibb, Sunshine Lake Pharma, aTyr Pharma, FibroGen, Boehringer Ingelheim, and others.

 

DelveInsight’s “Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Interstitial Lung Disease, historical and forecasted epidemiology as well as the Interstitial Lung Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Interstitial Lung Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Interstitial Lung Disease Market Forecast

 

Some of the key facts of the Interstitial Lung Disease Market Report:

  • The Interstitial Lung Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

  • In February 2025, Boehringer Ingelheim’s lung disease treatment, nerandomilast, has achieved success in a Phase III trial, positioning the company to pursue approval for its use in a second condition. Topline results from the Phase III FIBRONEER-ILD study (NCT05321082) indicate that nerandomilast enhanced lung function in patients with progressive fibrosing interstitial lung diseases (PF-ILDs), excluding idiopathic pulmonary fibrosis (IPF). Previously, the company conducted a separate IPF trial, which contributed to its new drug application (NDA) submission last year.

  • Key Interstitial Lung Disease Companies: J2H Biotech, Crystec Pharma, Apie Therapeutics, BLR Bio, ImmunoMet Therapeutics, AdAlta Limited, Genentech, Bristol-Myers Squibb, Sunshine Lake Pharma, aTyr Pharma, FibroGen, Boehringer Ingelheim, and others

  • Key Interstitial Lung Disease Therapies: J2H P1905, CR405, APT-101, BLR-200, M-156, AD-214, Vixarelimab, Abatacept, HEC585, Efzofitimod, Pamrevlumab, BI-1015550, and others

  • The Interstitial Lung Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Interstitial Lung Disease pipeline products will significantly revolutionize the Interstitial Lung Disease market dynamics.

 

Interstitial Lung Disease Overview

Interstitial lung disease (ILD) is a broad term that refers to a group of lung disorders characterized by inflammation and scarring (fibrosis) of the interstitium, which is the tissue that surrounds and supports the air sacs (alveoli) in the lungs. This inflammation and scarring can impair the ability of the lungs to function properly, leading to symptoms such as cough, shortness of breath, and decreased exercise tolerance.

 

Get a Free sample for the Interstitial Lung Disease Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/interstitial-lung-disease-market

 

Interstitial Lung Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Interstitial Lung Disease Epidemiology Segmentation:

The Interstitial Lung Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Interstitial Lung Disease

  • Prevalent Cases of Interstitial Lung Disease by severity

  • Gender-specific Prevalence of Interstitial Lung Disease

  • Diagnosed Cases of Episodic and Chronic Interstitial Lung Disease

 

Download the report to understand which factors are driving Interstitial Lung Disease epidemiology trends @ Interstitial Lung Disease Epidemiology Forecast

 

Interstitial Lung Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Interstitial Lung Disease market or expected to get launched during the study period. The analysis covers Interstitial Lung Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Interstitial Lung Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Interstitial Lung Disease Therapies and Key Companies

  • J2H P1905: J2H Biotech

  • CR405: Crystec Pharma

  • APT-101: Apie Therapeutics

  • BLR-200: BLR Bio

  • M-156: ImmunoMet Therapeutics

  • AD-214: AdAlta Limited

  • Vixarelimab: Genentech

  • Abatacept: Bristol-Myers Squibb

  • HEC585: Sunshine Lake Pharma

  • Efzofitimod: aTyr Pharma

  • Pamrevlumab: FibroGen

  • BI-1015550: Boehringer Ingelheim

 

Discover more about therapies set to grab major Interstitial Lung Disease market share @ Interstitial Lung Disease Treatment Landscape

 

Interstitial Lung Disease Market Drivers

  • Increase in prevalence of Interstitial Lung Disease (ILD), increase in geriatric population are some of the important factors that are fueling the Interstitial Lung Disease Market.

 

Interstitial Lung Disease Market Barriers

  • However, frequent misdiagnosis of the disease, costly and invasive diagnostic procedures and other factors are creating obstacles in the Interstitial Lung Disease Market growth.

 

Scope of the Interstitial Lung Disease Market Report

  • Study Period: 2019–2032

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Interstitial Lung Disease Companies: J2H Biotech, Crystec Pharma, Apie Therapeutics, BLR Bio, ImmunoMet Therapeutics, AdAlta Limited, Genentech, Bristol-Myers Squibb, Sunshine Lake Pharma, aTyr Pharma, FibroGen, Boehringer Ingelheim, and others

  • Key Interstitial Lung Disease Therapies: J2H P1905, CR405, APT-101, BLR-200, M-156, AD-214, Vixarelimab, Abatacept, HEC585, Efzofitimod, Pamrevlumab, BI-1015550, and others

  • Interstitial Lung Disease Therapeutic Assessment: Interstitial Lung Disease current marketed and Interstitial Lung Disease emerging therapies

  • Interstitial Lung Disease Market Dynamics: Interstitial Lung Disease market drivers and Interstitial Lung Disease market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Interstitial Lung Disease Unmet Needs, KOL’s views, Analyst’s views, Interstitial Lung Disease Market Access and Reimbursement

 

To know more about Interstitial Lung Disease companies working in the treatment market, visit @ Interstitial Lung Disease Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Interstitial Lung Disease Market Report Introduction

2. Executive Summary for Interstitial Lung Disease

3. SWOT analysis of Interstitial Lung Disease

4. Interstitial Lung Disease Patient Share (%) Overview at a Glance

5. Interstitial Lung Disease Market Overview at a Glance

6. Interstitial Lung Disease Disease Background and Overview

7. Interstitial Lung Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Interstitial Lung Disease

9. Interstitial Lung Disease Current Treatment and Medical Practices

10. Interstitial Lung Disease Unmet Needs

11. Interstitial Lung Disease Emerging Therapies

12. Interstitial Lung Disease Market Outlook

13. Country-Wise Interstitial Lung Disease Market Analysis (2019–2032)

14. Interstitial Lung Disease Market Access and Reimbursement of Therapies

15. Interstitial Lung Disease Market Drivers

16. Interstitial Lung Disease Market Barriers

17. Interstitial Lung Disease Appendix

18. Interstitial Lung Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Interstitial Lung Disease Market Poised for Significant Growth from 2023 to 2032, Reports DelveInsight | J2H Biotech, Crystec Pharma, Apie Therapeutics, BLR Bio, ImmunoMet Therapeutics, AdAlta

Endocarditis Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Lysovant, ContraFect, Basilea Pharmaceuticals

The Key Endocarditis Companies in the market include – Lysovant, ContraFect, Basilea Pharmaceuticals, Cubist Pharmaceuticals, Basilea Pharmaceutica, Merck Sharp & Dohme, and others.

The Endocarditis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Endocarditis pipeline products will significantly revolutionize the Endocarditis market dynamics.

 

DelveInsight’s “Endocarditis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Endocarditis, historical and forecasted epidemiology as well as the Endocarditis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Endocarditis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

 

To Know in detail about the Endocarditis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Endocarditis Market Forecast

 

Some of the key facts of the Endocarditis Market Report:

  • The Endocarditis market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • Endocarditis is an uncommon infection in the US; over 25% of cases affect people aged 60 years or above. Yet, it is also the fourth most common life-threatening infection after sepsis, pneumonia, and intra-abdominal abscess, with an estimated inpatient mortality rate between 15 and 30%.

  • According to the National Organisation for Rare Disorders (NORD, n.d.) Infective endocarditis appears to be approximately twice as common in men as women. In the past, disease onset occurred at an average age of 35.

  • Key Endocarditis Companies: Lysovant, ContraFect, Basilea Pharmaceuticals, Cubist Pharmaceuticals, Basilea Pharmaceutica, Merck Sharp & Dohme, and others

  • Key Endocarditis Therapies: Tonabacase (LSVT-1701), Exebacase(CF-301), ContraFect, daptomycin, Ceftobiprole medocaril, Daptomycin, and others

  • The Endocarditis epidemiology based on gender analyzed that endocarditis affects males and females in a ratio of 2:1

 

Endocarditis Overview

Endocarditis is defined as an inflammation of the endocardial surface of the heart. This may include heart valves, mural endocardium or the endocardium that covers prosthetic valves, pacemaker/defibrillator leads, and catheters. Infective and non-infective-related causes of endocarditis must be distinguished. The inflammation is related to a bacterial or fungal infection in most cases. Approximately 80% of infective endocarditis cases are caused by the bacteria streptococci and staphylococci.

 

Get a Free sample for the Endocarditis Market Report:

https://www.delveinsight.com/report-store/endocarditis-market

 

Endocarditis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Endocarditis Epidemiology Segmentation:

The Endocarditis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Endocarditis

  • Prevalent Cases of Endocarditis by severity

  • Gender-specific Prevalence of Endocarditis

  • Diagnosed Cases of Episodic and Chronic Endocarditis

 

Download the report to understand which factors are driving Endocarditis epidemiology trends @ Endocarditis Epidemiological Insights

 

Endocarditis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Endocarditis market or expected to get launched during the study period. The analysis covers Endocarditis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Endocarditis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Endocarditis Therapies and Key Companies

  • Tonabacase (LSVT-1701): Lysovant

  • Exebacase(CF-301): ContraFect

  • ContraFect: Basilea Pharmaceuticals

  • daptomycin: Cubist Pharmaceuticals

  • Ceftobiprole medocaril: Basilea Pharmaceutica

  • Daptomycin: Merck Sharp & Dohme

 

To know more about Endocarditis treatment, visit @ Endocarditis Medications

 

Scope of the Endocarditis Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Endocarditis Companies: Lysovant, ContraFect, Basilea Pharmaceuticals, Cubist Pharmaceuticals, Basilea Pharmaceutica, Merck Sharp & Dohme, and others

  • Key Endocarditis Therapies: Tonabacase (LSVT-1701), Exebacase(CF-301), ContraFect, daptomycin, Ceftobiprole medocaril, Daptomycin, and others

  • Endocarditis Therapeutic Assessment: Endocarditis current marketed and Endocarditis emerging therapies

  • Endocarditis Market Dynamics: Endocarditis market drivers and Endocarditis market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Endocarditis Unmet Needs, KOL’s views, Analyst’s views, Endocarditis Market Access and Reimbursement

 

Discover more about therapies set to grab major Endocarditis market share @ Endocarditis Treatment Landscape

 

Table of Contents

1. Endocarditis Market Report Introduction

2. Executive Summary for Endocarditis

3. SWOT analysis of Endocarditis

4. Endocarditis Patient Share (%) Overview at a Glance

5. Endocarditis Market Overview at a Glance

6. Endocarditis Disease Background and Overview

7. Endocarditis Epidemiology and Patient Population

8. Country-Specific Patient Population of Endocarditis

9. Endocarditis Current Treatment and Medical Practices

10. Endocarditis Unmet Needs

11. Endocarditis Emerging Therapies

12. Endocarditis Market Outlook

13. Country-Wise Endocarditis Market Analysis (2020–2034)

14. Endocarditis Market Access and Reimbursement of Therapies

15. Endocarditis Market Drivers

16. Endocarditis Market Barriers

17. Endocarditis Appendix

18. Endocarditis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Endocarditis Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Lysovant, ContraFect, Basilea Pharmaceuticals

Unstable Angina Market on Track for Major Expansion by 2032, According to DelveInsight | Tasly Pharmaceuticals, Arbor Pharmaceuticals

The Key Unstable Angina Companies in the market include – Tasly Pharmaceuticals, Arbor Pharmaceuticals, and others.

 

The Unstable Angina market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Unstable Angina pipeline products will significantly revolutionize the Unstable Angina market dynamics.

 

DelveInsight’s “Unstable Angina Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Unstable Angina, historical and forecasted epidemiology as well as the Unstable Angina market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Unstable Angina market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

 

To Know in detail about the Unstable Angina market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Unstable Angina Market Insights

 

Some of the key facts of the Unstable Angina Market Report:

  • The Unstable Angina market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

  • In November 2024, Saghmos is developing ST-62516 (trimetazidine), a cardiorenal metabolic modulator aimed at lowering the risk of Acute Kidney Injury (AKI) and Major Adverse Cardiac and Kidney Events (MACKE) following contrast-based procedures like percutaneous coronary intervention (PCI). In the US, over one million PCI procedures are performed annually on patients with unstable angina, with around half having additional health conditions that affect PCI safety. This represents a significant unmet medical need, as no FDA-approved treatments currently exist to prevent or manage AKI and MACKE. Saghmos Therapeutics is partnering with the Duke Clinical Research Institute to refine and execute the Phase 3 trial for ST-62516.

  • Coronary heart disease (CHD) impacts over 17 million adults in the United States. Of the 17 million Americans affected, 55% of those are male. Angina affects 10 million people in the United States

  • According to the study of Nathan Messas, Unstable Angina or Angina pectoris is the most prevalent manifestation of myocardial ischemia and coronary artery disease (CAD), affecting up to 9 million patients in the United States

  • Key Unstable Angina Companies: Tasly Pharmaceuticals, Arbor Pharmaceuticals, and others

  • Key Unstable Angina Therapies: T89, AR36, and others

  • The Unstable Angina epidemiology based on gender analyzed that it can be concluded that Unstable Angina is more common in males than female

 

Unstable Angina Overview

Unstable angina is a type of chest pain that occurs suddenly and unpredictably due to reduced blood flow to the heart. It is a medical emergency and a warning sign of an impending heart attack. Unlike stable angina, it can occur at rest, lasts longer, and may not be relieved by medication or rest. It results from the rupture of a plaque in the coronary artery, leading to partial blockage. Immediate treatment is essential to restore blood flow and prevent heart damage.

 

Get a Free sample for the Unstable Angina Market Report:

https://www.delveinsight.com/report-store/unstable-angina-market

 

Unstable Angina Market

The dynamics of the Unstable Angina market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.

“The emerging pipeline for the treatment of Unstable Angina have few candidates. These products are in mid or last stage of investigation. With the launch of emerging therapies the total market of Unstable Angina is supposed to experience immense changes in the future”

 

Unstable Angina Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Unstable Angina Epidemiology Segmentation:

The Unstable Angina market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Unstable Angina

  • Prevalent Cases of Unstable Angina by severity

  • Gender-specific Prevalence of Unstable Angina

  • Diagnosed Cases of Episodic and Chronic Unstable Angina

 

Download the report to understand which factors are driving Unstable Angina epidemiology trends @ Unstable Angina Epidemiological Insights

 

Unstable Angina Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Unstable Angina market or expected to get launched during the study period. The analysis covers Unstable Angina market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Unstable Angina Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Unstable Angina Therapies and Key Companies

  • T89: Tasly Pharmaceuticals

  • AR36: Arbor Pharmaceuticals

 

To know more about Unstable Angina treatment, visit @ Unstable Angina Medications

 

Scope of the Unstable Angina Market Report

  • Study Period: 2019–2032

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Unstable Angina Companies: Tasly Pharmaceuticals, Arbor Pharmaceuticals, and others

  • Key Unstable Angina Therapies: T89, AR36, and others

  • Unstable Angina Therapeutic Assessment: Unstable Angina current marketed and Unstable Angina emerging therapies

  • Unstable Angina Market Dynamics: Unstable Angina market drivers and Unstable Angina market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Unstable Angina Unmet Needs, KOL’s views, Analyst’s views, Unstable Angina Market Access and Reimbursement

 

Discover more about therapies set to grab major Unstable Angina market share @ Unstable Angina Treatment Landscape

 

Table of Contents

1. Unstable Angina Market Report Introduction

2. Executive Summary for Unstable Angina

3. SWOT analysis of Unstable Angina

4. Unstable Angina Patient Share (%) Overview at a Glance

5. Unstable Angina Market Overview at a Glance

6. Unstable Angina Disease Background and Overview

7. Unstable Angina Epidemiology and Patient Population

8. Country-Specific Patient Population of Unstable Angina

9. Unstable Angina Current Treatment and Medical Practices

10. Unstable Angina Unmet Needs

11. Unstable Angina Emerging Therapies

12. Unstable Angina Market Outlook

13. Country-Wise Unstable Angina Market Analysis (2019–2032)

14. Unstable Angina Market Access and Reimbursement of Therapies

15. Unstable Angina Market Drivers

16. Unstable Angina Market Barriers

17. Unstable Angina Appendix

18. Unstable Angina Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Unstable Angina Market on Track for Major Expansion by 2032, According to DelveInsight | Tasly Pharmaceuticals, Arbor Pharmaceuticals

Portal Hypertension Market Growth Projections 2023-2032: DelveInsight Analysis | Boehringer Ingelheim, Gilead Sciences, Novartis, Cumberland Pharma, Conatus, Onyx Therapeutics, Inc.

The Key Portal Hypertension Companies in the market include – Boehringer Ingelheim, Galectin Therapeutics Inc., Onyx Therapeutics, Inc., Novartis, Cumberland Pharma, Conatus Pharma, Ferozsons Laboratories Ltd., Histogen, Gilead Sciences, Galectin Therapeutics Inc., and others.

 

DelveInsight’s “Portal Hypertension Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Portal Hypertension, historical and forecasted epidemiology as well as the Portal Hypertension market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Portal Hypertension market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Portal Hypertension Market Forecast

 

Some of the key facts of the Portal Hypertension Market Report:

  • The Portal Hypertension market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

  • In May 2025, Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company specializing in innovative treatments for metabolic dysfunction-associated steatohepatitis (MASH), today reported encouraging two-year outcomes from the open-label compensated MASH cirrhosis (F4c) cohort of the Phase 3 MAESTRO-NAFLD-1 trial evaluating Rezdiffra. The 122 patients enrolled showed notable improvements from baseline in liver stiffness, liver fat content, fibrosis biomarkers, liver volume, and clinically significant portal hypertension (CSPH) risk scores.

  • Around 2000 Americans per 100,000 have liver cirrhosis in the United States, and more than 90% of those who have cirrhosis go on to develop portal hypertension, according to National Institutes of Health (n.d.)

  • Although it is likely similar to that of the US, the international incidence of portal hypertension is similarly unknown, with variances mostly in the underlying reasons. The major causes of portal hypertension and esophageal varices in Western countries are alcoholic and viral cirrhosis; at the time of diagnosis, gastroesophageal varices are present in 30% of patients with compensated cirrhosis and 60–70% of patients with decompensated cirrhosis

  • Portal hypertension, a disease that precedes the bulk of cirrhotic patients’ deaths, eventually develops in about 90% of cirrhotic patients

  • Key Portal Hypertension Companies: Boehringer Ingelheim, Galectin Therapeutics Inc., Onyx Therapeutics, Inc., Novartis, Cumberland Pharma, Conatus Pharma, Ferozsons Laboratories Ltd., Histogen, Gilead Sciences, Galectin Therapeutics Inc., and others

  • Key Portal Hypertension Therapies: BI 685509, GR-MD-02, Sorafenib, Serelaxin, Ifetroban, IDN-6556, Terlipressin, Emricasan, Ambrisentan, belapectin, and others

  • The Portal Hypertension epidemiology based on gender analyzed that portal hypertension affects males slightly more than females

  • The Portal Hypertension market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Portal Hypertension pipeline products will significantly revolutionize the Portal Hypertension market dynamics.

 

Portal Hypertension Overview

A rise in the pressure inside the portal vein, which conducts blood from the digestive system to the liver, is known as portal hypertension. A obstruction in the blood flow through the liver is the root cause of the rise in pressure. Large veins (varices) grow across the oesophagus and stomach to get past the blockage as a result of increased pressure in the portal vein. The varices deteriorate and become more prone to bleeding.

 

Get a Free sample for the Portal Hypertension Market Report

https://www.delveinsight.com/report-store/portal-hypertension-market

 

Portal Hypertension Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Portal Hypertension Epidemiology Segmentation:

The Portal Hypertension market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Portal Hypertension

  • Prevalent Cases of Portal Hypertension by severity

  • Gender-specific Prevalence of Portal Hypertension

  • Diagnosed Cases of Episodic and Chronic Portal Hypertension

 

Download the report to understand which factors are driving Portal Hypertension epidemiology trends @ Portal Hypertension Epidemiology Forecast

 

Portal Hypertension Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Portal Hypertension market or expected to get launched during the study period. The analysis covers Portal Hypertension market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Portal Hypertension Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Portal Hypertension Therapies and Key Companies

  • BI 685509: Boehringer Ingelheim

  • GR-MD-02: Galectin Therapeutics Inc.

  • Sorafenib: Onyx Therapeutics, Inc.

  • Serelaxin: Novartis

  • Ifetroban: Cumberland Pharma

  • IDN-6556: Conatus Pharma

  • Terlipressin: Ferozsons Laboratories Ltd.

  • Emricasan: Histogen

  • Ambrisentan: Gilead Sciences

  • belapectin: Galectin Therapeutics Inc.

 

Discover more about therapies set to grab major Portal Hypertension market share @ Portal Hypertension Treatment Market

 

Scope of the Portal Hypertension Market Report

  • Study Period: 2019–2032

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Portal Hypertension Companies: Boehringer Ingelheim, Galectin Therapeutics Inc., Onyx Therapeutics, Inc., Novartis, Cumberland Pharma, Conatus Pharma, Ferozsons Laboratories Ltd., Histogen, Gilead Sciences, Galectin Therapeutics Inc., and others

  • Key Portal Hypertension Therapies: BI 685509, GR-MD-02, Sorafenib, Serelaxin, Ifetroban, IDN-6556, Terlipressin, Emricasan, Ambrisentan, belapectin, and others

  • Portal Hypertension Therapeutic Assessment: Portal Hypertension current marketed and Portal Hypertension emerging therapies

  • Portal Hypertension Market Dynamics: Portal Hypertension market drivers and Portal Hypertension market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Portal Hypertension Unmet Needs, KOL’s views, Analyst’s views, Portal Hypertension Market Access and Reimbursement

 

To know more about Portal Hypertension companies working in the treatment market, visit @ Portal Hypertension Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Portal Hypertension Market Report Introduction

2. Executive Summary for Portal Hypertension

3. SWOT analysis of Portal Hypertension

4. Portal Hypertension Patient Share (%) Overview at a Glance

5. Portal Hypertension Market Overview at a Glance

6. Portal Hypertension Disease Background and Overview

7. Portal Hypertension Epidemiology and Patient Population

8. Country-Specific Patient Population of Portal Hypertension

9. Portal Hypertension Current Treatment and Medical Practices

10. Portal Hypertension Unmet Needs

11. Portal Hypertension Emerging Therapies

12. Portal Hypertension Market Outlook

13. Country-Wise Portal Hypertension Market Analysis (2019–2032)

14. Portal Hypertension Market Access and Reimbursement of Therapies

15. Portal Hypertension Market Drivers

16. Portal Hypertension Market Barriers

17. Portal Hypertension Appendix

18. Portal Hypertension Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Portal Hypertension Market Growth Projections 2023-2032: DelveInsight Analysis | Boehringer Ingelheim, Gilead Sciences, Novartis, Cumberland Pharma, Conatus, Onyx Therapeutics, Inc.